Amarillo National Bank Sells 150 Shares of Danaher Co. (NYSE:DHR)

Amarillo National Bank cut its holdings in Danaher Co. (NYSE:DHR) by 9.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,525 shares of the conglomerate’s stock after selling 150 shares during the quarter. Amarillo National Bank’s holdings in Danaher were worth $424,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of DHR. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher in the second quarter worth about $25,000. nVerses Capital LLC bought a new stake in shares of Danaher in the second quarter worth about $25,000. Redmont Wealth Advisors LLC bought a new stake in shares of Danaher in the first quarter worth about $30,000. MFA Wealth Advisors LLC bought a new stake in shares of Danaher in the second quarter worth about $51,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Danaher in the second quarter worth about $51,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

DHR stock opened at $245.39 on Friday. The firm has a market capitalization of $181.76 billion, a price-to-earnings ratio of 41.59, a PEG ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a 50 day moving average price of $269.52 and a 200-day moving average price of $260.42. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.02 earnings per share. Equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Linda Filler sold 3,928 shares of Danaher stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the completion of the sale, the director now directly owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,059 shares of company stock valued at $8,400,897 over the last 90 days. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of several research analyst reports. Leerink Partners raised their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. UBS Group lowered their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday. TD Cowen raised their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday. Bank of America raised their price objective on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Finally, Barclays lowered their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $287.28.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.